-
Mashup Score: 3Overview | Dupilumab for treating moderate to severe atopic dermatitis | Guidance | NICE - 8 month(s) ago
Evidence-based recommendations on dupilumab (Dupixent) for treating moderate to severe atopic dermatitis in adults
Source: www.nice.org.ukCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 5
This guideline covers the general principles for managing intravenous (IV) fluid therapy in hospital inpatients aged 16 and over with a range of conditions. It aims to help prescribers understand the optimal amount and composition of IV fluids to be administered and the best rate at which to give them, to improve fluid prescribing and outcomes among people in hospital. It does not cover pregnant women, and those with severe liver or renal disease, diabetes or burns
Source: www.nice.org.ukCategories: General Medicine News, Hem/OncsTweet-
RT @AJMI_online: Pérdida de electrolitos de acuerdo al sitio corporal y a la patología: https://t.co/sYfbkJHq23 https://t.co/6F7ihK1bFh
-
-
Mashup Score: 13Overview | Ovarian cancer: identifying and managing familial and genetic risk | Guidance | NICE - 8 month(s) ago
This guideline covers assessing the familial and genetic risk of having a pathogenic variant associated with ovarian cancer in adults
Source: www.nice.org.ukCategories: General Medicine News, Oncologists2Tweet-
https://t.co/jDGZZj21uX Delighted to see the new NICE Guideline NG241 out on - Ovarian cancer: identifying and managing familial and genetic risk. Huge effort over 2.5 years. Big Thank You to the entire Committee and the NICE team as well as stakeholders contributing to this
-
-
Mashup Score: 7Overview | Delirium: prevention, diagnosis and management in hospital and long-term care | Guidance | NICE - 9 month(s) ago
This guideline covers diagnosing and treating delirium in people aged 18 and over in hospital and in long-term residential care or a nursing home. It also covers identifying people at risk of developing delirium in these settings and preventing onset. It aims to improve diagnosis of delirium and reduce hospital stays and complications
Source: www.nice.org.ukCategories: General Medicine News, Hem/OncsTweet-
RT @sundusjawad1: Talking about guidelines, check out the @NICEComms #delirium guidelines and QStandards here https://t.co/4CKpT6LFBa And…
-
-
Mashup Score: 87Recommendations | Intravenous fluid therapy in adults in hospital | Guidance | NICE - 9 month(s) ago
This guideline covers the general principles for managing intravenous (IV) fluid therapy in hospital inpatients aged 16 and over with a range of conditions. It aims to help prescribers understand the optimal amount and composition of IV fluids to be administered and the best rate at which to give them, to improve fluid prescribing and outcomes among people in hospital. It does not cover pregnant women, and those with severe liver or renal disease, diabetes or burns
Source: www.nice.org.ukCategories: General Medicine News, CardiologistsTweet-
RT @ZHeart11768530: 🔴 Intravenous fluid therapy in adults in hospital 👉Algorithms for IV fluid therapy https://t.co/Wl0dlSlA2D #TipsForNew…
-
-
Mashup Score: 1300 people to benefit from new treatment for advanced breast cancer recommended by NICE following price deal - 10 month(s) ago
The recommendation reverses NICE’s earlier draft decision not to recommend talazoparib for adults with BRCA 1 or 2 mutated HER2-negative locally advanced or metastatic breast cancer after prior chemotherapy. It follows the offer of an increased discount to the price of talazoparib, also called Talzenna, by the company (Pfizer). Once the draft guidance becomes final next month it will mean NICE will have made positive recommendations in all 20 of its completed appraisals of breast cancer treatments since
Source: www.nice.org.ukCategories: General Medicine News, Hem/OncsTweet-
300 people to benefit from new treatment for advanced breast cancer recommended by NICE following price deal@- this is great news. In my anecdotal experience Talazoparib is an excellent drug with few side effects. https://t.co/owUNqjzaxK
-
-
Mashup Score: 3
Evinacumab for treating homozygous familial hypercholesterolaemia in people aged 12 years and over [ID2704]
Source: www.nice.org.ukCategories: General Medicine News, Cardiologists1Tweet-
NICE 🇬🇧 are hopefully going to give this a positive recommendation in early 2024 https://t.co/TSbKBj6Q6L How about in France 🇫🇷 @SABOURETCardio ? https://t.co/hmv98RYMck
-
-
Mashup Score: 0First treatment to be recommended by NICE at the same time it is approved for advanced lymphoma in the UK - 1 year(s) ago
NICE has recommended glofitamab as a new treatment option for adults with relapsed or refractory diffuse large B cell lymphoma after 2 or more systemic treatments in final guidance published today (17 October 2023). Today’s recommendation for its use in the NHS coincides with glofitamab receiving its licence from the Medicines and Healthcare Products Regulatory Agency (MHRA). Lymphoma is a form of blood cancer that affects the immune system. It develops from a type of white blood cell, called a lymphocyte
Source: www.nice.org.ukCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🚨 NEWS 🚨 @NICEComms recommends glofitamab for the treatment of adult patients with relapsed or refractory diffuse large B-cell #lymphoma who have received two or more previous systemic treatments. Read more here: https://t.co/U0mjp7YHgu #lymsm #MedNews https://t.co/6znRbjhpuA
-
-
Mashup Score: 2
Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction [ID3945]
Source: www.nice.org.ukCategories: Cardiologists, Latest HeadlinesTweet-
Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction [ID3945] | Guidance | NICE Expected publication date: 1st November 2023 #heartfailure https://t.co/xIvIhgQ9BD
-
-
Mashup Score: 10
Early value assessment (EVA) guidance on artificial intelligence (AI)-derived software to analyse chest X-rays for suspected lung cancer in primary care referrals
Source: www.nice.org.ukCategories: Cardiologists, Latest HeadlinesTweet-
RT @DrHughHarvey: NICE doesn't recommend CXR AI yet https://t.co/naGGeb5p2k Unsurprisingly - lack of human-AI prospective evaluation, and…
-
What did I say abt wasting scarce @NHSEngland resources +++ on worthless drugs @sib313 @PharmRJ ? @NICEComms has a TAG on Dupilimumab https://t.co/rw3j441t7T https://t.co/gHqpVfzqfP